Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
OMass Therapeutics is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
AdvanCell develops targeted alpha radiopharmaceutical therapies for cancer and supports their development and manufacturing.
CereVasc is a medical device company that develops a minimally invasive treatment option for communicating hydrocephalus.
Apreo Health is developer of medical apparatus designed for diagnosing or treating respiratory, pulmonary, and lung conditions.
Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.
Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.
Century Therapeutics is a biotechnology company that develops cell therapies for hematological and solid tumor malignancies.
Kestra Medical Technologies offers wearable medical devices which collects, store, and communicate patients vital performance data.
Nuvalent is a biopharmaceutical company that develops targeted therapies for cancer by designing small-molecule medicines.
X4 Pharmaceuticals is a clinical-stage oncology company developing oral small molecule CXCR4 antagonists for the treatment.
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Merida Biosciences is a biotech company focused on developing precision treatments, particularly for autoimmune diseases.
Heartflow is a medical technology company that provides various methods of diagnosis and treatment of cardiovascular disease.
Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.
Timberlyne Therapeutics is a biopharmaceutical company that develops therapies for autoimmune diseases.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
Replimune Group develop the next generation of ‘oncolytic immunotherapies’ for the treatment of cancer.
Serán Bioscience is a contract development and manufacturing organization.
Cardurion is a cardiovascular biotechnology company developing therapeutics for the treatment of heart failure and cardiovascular diseases.
Areteia Therapeutics is a biotechnology company committed to putting asthma patients in better control of their disease.
Syremis Therapeutics is developing novel medicines to make a profound impact on the treatment of mental health disorders.
Bain Capital Life Sciences has invested in 59 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Bain Capital Life Sciences's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 16 different industry categories.
Among tracked funding rounds, Nuvalent received $500.0M in a Post-IPO Secondary round. Bain Capital Life Sciences's total known invested capital is $10.0B.
Bain Capital Life Sciences's average investment size is $169.7M across its portfolio of 59 companies.
Recent Bain Capital Life Sciences portfolio additions include OMass Therapeutics, ADC Therapeutics, AdvanCell, CereVasc, Apreo Health. These companies were founded in 2020 or later.